冬眠心肌与瘢痕对缺血性左室功能不全患者CABG获益的影响
该回顾性队列纳入507例接受18F-FDG PET与心脏磁共振钆延迟强化活性检测的缺血性左室功能不全患者,比较CABG与单纯药物治疗。中位随访71.5个月,校正后CABG与更低的全因死亡及复合终点风险相关,且各冬眠与瘢痕亚组均获益。
要点
- CABG与全因死亡风险降低相关(HR 0.249;95%CI 0.154-0.428;P<.001)。
- 按冬眠10%、瘢痕26%切点分的4个亚组中CABG均与良好结局相关。
- 冬眠心肌与瘢痕的范围和严重程度似不影响CABG疗效。
核心结论
- 冬眠心肌与瘢痕的范围和严重程度似不影响缺血性左室功能不全患者CABG的疗效。
研究设计与样本
- 回顾性队列研究,连续纳入2015年1月至2018年4月接受18F-FDG PET与心脏磁共振钆延迟强化活性检测的缺血性左室功能不全患者507例。
- 主要终点为全因死亡;次要终点为心血管死亡、心血管住院、心脏移植、血运重建、植入式心律转复除颤器置入或非致死性卒中的复合终点。
- 采用Cox模型计算CABG与单纯药物治疗在不同冬眠与瘢痕水平亚组中的风险比(HR)及置信区间。
主要发现
- 中位随访71.5个月,98例达到主要终点,194例达到次要终点。
- 校正后CABG组全因死亡风险低于单纯药物治疗(HR 0.249;95%CI 0.154-0.428;P<.001)。
- 校正后CABG组次要终点发生率低于单纯药物治疗(HR 0.457;95%CI 0.318-0.658;P<.001)。
- 按最佳切点(冬眠10%、瘢痕26%)划分的4个亚组中,CABG均与良好结局相关。
关键数值与推荐
- 冬眠心肌最佳切点为10%,瘢痕最佳切点为26%。
- 全因死亡:HR 0.249;95%CI 0.154-0.428;P<.001。
- 次要复合终点:HR 0.457;95%CI 0.318-0.658;P<.001。
临床怎么用
- 对缺血性左室功能不全患者,CABG的生存获益在各冬眠与瘢痕水平亚组中均可见,活性评估结果不宜单独作为否定手术的依据。
局限性
- 为单中心回顾性研究,样本量507例,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The significance of evaluating myocardial viability in making decisions regarding coronary artery bypass grafting (CABG) for patients with ischemic left ventricular dysfunction (ILVD) remains controversial. This study aimed to examine the impact of integrated assessment of hibernating myocardium and scars on the survival benefit associated with CABG in patients with ILVD. METHODS: Consecutive patients with ILVD who underwent fluorine-18 fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance imaging with late gadolinium enhancement viability testing from January 2015 and April 2018 were retrospectively enrolled. The primary end point was all-cause death. The secondary end point was a composite of cardiovascular death, cardiovascular hospitalization, heart transplantation, revascularization, insertion of an implantable cardioverter-defibrillator, or nonfatal stroke. Cox models calculated hazard ratios (HRs) and CIs for CABG vs medical therapy alone for subgroups with different levels of hibernation and scars. RESULTS: During a median follow-up of 71.5 months in 507 patients, 98 patients reached the primary end point and 194 reached the secondary end point. After adjustment, CABG was associated with lower risks of all-cause mortality (HR, 0.249; 95% CI, 0.154-0.428; P<.001) and lower incidences of secondary outcomes (HR, 0.457; 95% CI, 0.318-0.658; P<.001) compared with medical treatment alone in the population. Across all 4 subgroups classified by the optimal cutoff value (10% hibernation and 26% scar), CABG was associated with favorable outcomes regardless of the hibernation and scar level. CONCLUSIONS: The extent and severity of hibernating myocardium and scars appear not to influence the effects of CABG in patients with ILVD.
引用
- Song S, Han X, Ma X, et al. Impact of Myocardial Hibernation and Scar on Benefits From CABG in Ischemic Left Ventricular Dysfunction. Ann Thorac Surg. 2025. PMID: 39894429. doi:10.1016/j.athoracsur.2025.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。